| Autor: |
Darren R. Carpizo, S. David Kimball, Stewart N. Loh, David A. Boothman, John Gilleran, Alan J. Blayney, Bing Na, Tracy Withers, Yue Liu, Adam R. Blanden, Anthony F. Bencivenga, Xin Yu, Saif Zaman |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1535-7163.22505854 |
| Popis: |
Suppl. Fig. S1 display ZMC1 structure. Suppl. Fig. S2 showed no synergy in combination treatment of ZMC1 and Adriamycin or IR. Suppl. Fig. S3 showed synergy in Detroit 562 cells by combination treatment of ZMC1 and Irinotecan in the presence of GSH. Suppl. Fig. S4 showed combination response of ZMC1 and DNA damaging reagent (Irinotecan) in the presence of GSH. Suppl. Fig. S5 showed combination response to ZMC1 and Etoposide is mutant p53 dependent. Suppl. Fig. S6 showed measurement of KCuZMC1 using EGTA competition assay. Suppl. Fig. S7 displayed NTA competition assay for determining KCuC12. Suppl. Fig. S8 showed combination response to MEE or DEE and Etoposide is mutant p53 dependent. Suppl. Fig. S9 showed 5 combination treatments of ZMC1 and other targeted therapy drugs (A) b-Lapachone (b-Lap), (B) ThioNa, (C) 6-AN, (D) ABT-199, (E) Nutlin 3a. Suppl. Fig. S10 showed that the combination treatment of ZMC1 and ABT-199 promoted more apoptosis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
